Table 2.

Initial data set and validation set results according to axillary nodal involvement

	Initial set					Validation set
	pN0		i+/mi/macro			pN0		i+/mi/macro
	Nb	%	Nb	%	p	Nb	%	Nb	%	p
Nb patients	5507		2874			2746		1445
Age median (range)	59 (18–101)		55 (20–98)			59 (18–100)		56 (22–90)
<  60	3001	55	1856	65	< 0.0001	1464	53	910	63	< 0.0001
61–65	818	15	348	12		443	16	201	14
>  65	1686	31	669	23		836	30	334	23
Tumor size (median)	12		19			12		20
<  10	2642	49	494	17	< 0.0001	1340	49	225	16	< 0.0001
11 to 20	2185	40	1183	41		1081	40	604	42
>  20	608	11	1176	41		294	11	601	42
Tumor type
Ductal	4244	77	2278	79	< 0.0001	2133	78	1138	79	< 0.0001
Lobular	711	13	399	14		332	12	203	14
Mixt	73	1	71	2		38	1	44	3
Others	473	9	126	4		241	9	59	4
Grade
1	2142	39	749	26	< 0.0001	1007	37	348	24	< 0.0001
2	2410	44	1390	49		1245	46	711	49
3	887	16	724	25		459	17	378	26
LVI
Negative	4077	89	1584	59	< 0.0001	2004	89	765	58	< 0.0001
Positive	510	11	1085	41		256	11	549	42
Estrogen receptors
negative	747	14	399	14	0.6964	371	14	213	15	0.296
positive	4757	86	2470	86		2371	86	1230	85
Progesterone receptors
negative	1568	30	713	26	0.0004	782	30	401	29	0.6346
positive	3678	70	2023	74		1841	70	980	71
Hormonal receptors
negative	660	12	360	13	0.4835	337	12	184	13	0.6948
positive	4841	88	2508	87		2406	88	1258	87
Her2 status
negative	5837	91	1733	87	< 0.0001	2909	92	871	86	< 0.0001
positive	563	9	248	13		269	8	142	14
Tumor sub types
Luminal A	4100	75	1926	67	< 0.0001	2029	75	943	66	< 0.0001
Luminal B Her2-	364	7	392	14		217	8	205	14
HR+ Her2+	336	6	185	6		140	5	105	7
HR- Her 2+	151	3	137	5		93	3	69	5
Triple Negative	509	9	223	8		244	9	115	8
Clinical size
T0	1458	28	373	14	< 0.0001	756	29	177	13	< 0.0001
T1	3166	61	1378	50		1565	60	675	48
T2	546	11	837	30		272	10	460	33
> T3	18	0	169	6		16	1	80	5